chr17-35103297-C-T
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The ENST00000345365.11(RAD51D):c.695G>A(p.Arg232Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000859 in 1,611,706 control chromosomes in the GnomAD database, including 8 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R232G) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000345365.11 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RAD51D | NM_002878.4 | c.695G>A | p.Arg232Gln | missense_variant | 8/10 | ENST00000345365.11 | NP_002869.3 | |
RAD51L3-RFFL | NR_037714.1 | n.447G>A | non_coding_transcript_exon_variant | 4/7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD51D | ENST00000345365.11 | c.695G>A | p.Arg232Gln | missense_variant | 8/10 | 1 | NM_002878.4 | ENSP00000338790 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00419 AC: 638AN: 152124Hom.: 6 Cov.: 32
GnomAD3 exomes AF: 0.00127 AC: 312AN: 245490Hom.: 1 AF XY: 0.000958 AC XY: 127AN XY: 132598
GnomAD4 exome AF: 0.000510 AC: 745AN: 1459464Hom.: 2 Cov.: 32 AF XY: 0.000451 AC XY: 327AN XY: 725784
GnomAD4 genome AF: 0.00420 AC: 640AN: 152242Hom.: 6 Cov.: 32 AF XY: 0.00390 AC XY: 290AN XY: 74430
ClinVar
Submissions by phenotype
not specified Benign:7
Benign, no assertion criteria provided | clinical testing | Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute | - | - - |
Benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Sep 11, 2019 | - - |
Benign, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Aug 15, 2023 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Feb 11, 2014 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 20, 2017 | - - |
Benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jul 02, 2021 | - - |
Breast-ovarian cancer, familial, susceptibility to, 4 Benign:4
Likely benign, criteria provided, single submitter | clinical testing | Counsyl | Jun 13, 2016 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Apr 06, 2023 | This variant is considered likely benign. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. - |
Likely benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Sep 18, 2023 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
not provided Benign:3
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2024 | RAD51D: BP4, BS1 - |
Likely benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Hereditary cancer-predisposing syndrome Benign:3
Likely benign, no assertion criteria provided | clinical testing | True Health Diagnostics | Sep 13, 2017 | - - |
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 07, 2014 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Dec 23, 2014 | - - |
Breast and/or ovarian cancer Benign:1
Benign, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | May 18, 2022 | - - |
Malignant tumor of breast Benign:1
Likely benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The RAD51D p.Arg232Gln variant was identified in 16 of 10424 proband chromosomes (frequency: 0.002) from individuals or families with breast cancer, ovarian cancer, primary myelofibrosis or lynch syndrome and was not identified in 2120 control chromosomes from healthy individuals (Gutierrez-Enriquez 2013, Loveday 2011, Pratz 2016, Tung 2015, Yurgelun 2015). The variant was also identified in dbSNP (ID: rs28363283) as "With other allele", and in ClinVar (classified as benign by GeneDx, Ambry Genetics, Invitae, Color Genomics, Quest Diagnostics Nichols Institute San Juan Capistrano; as likely benign by Counsyl). The variant was not identified in the Cosmic database. The variant was identified in control databases in 418 of 271350 chromosomes (3 homozygous) at a frequency of 0.002 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). It was observed in the following populations: African in 328 of 23508 chromosomes (freq: 0.01), Other in 7 of 6346 chromosomes (freq: 0.001), Latino in 48 of 33802 chromosomes (freq: 0.001), European in 20 of 123952 chromosomes (freq: 0.0002), Ashkenazi Jewish in 14 of 9952 chromosomes (freq: 0.001), and South Asian in 1 of 30008 chromosomes (freq: 0.00003); it was not observed in the East Asian, and Finnish populations. The p.Arg232 residue is conserved in mammals but not in more distantly related organisms however four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. This variant was identified in an individual with HBOC and a co-occurring BRCA2 variant (c.6405_6409del) increasing the likelihood the RAD51D c.695G>A variant may not have clinical significance. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at